Ziv-aflibercept Efficacy in Better Regulating AMD

Exclusion Criteria

• •Active intraocular inflammation or infection
• •History of vitreous hemorrhage within three months prior to Day 1 of the study
• •Uncontrolled ocular hypertension or glaucoma in the study eye (defined as Intraocular Pressure ("IOP") \>25 mm Hg or a Cup to Disc ratio \> 0.8 despite treatment with anti-glaucoma medication) or any such condition which the investigator feels may warrant a glaucoma filtering surgery during the study
• •History of stroke within the last three months prior to Day 1 of the study
• •History of myocardial infarction within the last three months prior to Day 1 of the study
• •Undergone intraocular surgery or laser treatments within the last three months,
• •Significant Epiretinal Membrane ("ERM") or Vitreomacular Traction ("VMT") causing distortion of macular anatomy
• •No use of ocular corticosteroids within the last six months and no use of systemic corticosteroids at a dose of \>10 mg/day
• •Not have active malignancies within the last 12 months except appropriately treated carcinoma in situ of the cervix, melanoma, and prostate cancers treated with a curative intent
• •Inability to comply with study or follow-up procedures
• •Women who may become pregnant or lactating or intend to become pregnant during the study
• •Women who are of childbearing potential, including women who have had tubal ligation, must have a blood test within 21 days prior to Day 1 of the study. A woman is considered to not be of childbearing potential if she is postmenopausal or has undergone hysterectomy and/or bilateral oophorectomy. Postmenopausal is defined as 12 consecutive months with no menses without an alternative medical cause.